deltatrials
Completed PHASE2 NCT00002515

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer

Myeloablative Chemotherapy With Bone Marrow Rescue For Rare Poor-Prognosis Cancers

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Childhood Germ Cell Tumor Extragonadal Germ Cell Tumor Head and Neck Cancer Kidney Cancer Liver Cancer Lymphoma Neuroblastoma Ovarian Cancer Retinoblastoma Sarcoma Testicular Germ Cell Tumor
Interventions autologous bone marrow transplantation bone marrow ablation with stem cell support carboplatin filgrastim in vitro-treated bone marrow transplantation thiotepa topotecan hydrochloride
Updated 5 times since 2017 Last updated: Jun 20, 2013 Started: Oct 31, 1992 Primary completion: Apr 30, 2005 Completion: Apr 30, 2005

A PHASE2 clinical study on Childhood Germ Cell Tumor and Extragonadal Germ Cell Tumor, this trial is completed. The trial is conducted by Memorial Sloan Kettering Cancer Center and has accumulated 5 data snapshots since 1992. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Oct 1992

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States